Specifically, PPARγ induced PD-L1 degradation in malignant cells, which contributes to enhancing the sensitivity to immunotherapy, whereas PPARγ activation in myeloid cells promotes lung cancer progression and metastasis. The gene discussed is PPARG; the disease is lung cancer.